Neurologist Reveals Insider Information

A Michigan University clinical researcher allegedly supplied a fund manager with information about drug trial results that the fund used to rake in more than $270 million.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Flickr, jollyUKSidney Gilman, former chair of the neurology department at the University of Michigan Medical School, has been sued by federal authorities for providing a hedge fund information about clinical trials for an Alzheimer’s drug under development by Elan and Wyeth that led to the fund dumping stocks and making more than $270 million.

The man at the head of the investigation is Mathew Martoma, a portfolio manager at hedge fund firm SAC Capital Advisors, although prosecutors are also looking into wrongdoing by the company’s owner Steven Cohen. Martoma is charged with making trades based on information from Gilman.

Preet Bharara, the United States attorney who brought the case to court, called the transaction “the most lucrative insider trading scheme ever charged,” in an interview with The New York Times.

Gilman, who is 80, served as a consultant to Martoma, receiving nearly $108,000 for his expertise. He also helped oversee the Alzheimer’s trial and is accused of providing information regarding, at first, the drug’s positive results, and later, it’s failure, allowing Martoma to invest and pull out at the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Edyta Zielinska

    This person does not yet have a bio.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide